Home Featured Page 153

Featured

Latest

No Questions Asked: FDA’s Psychedelics Public Hearing

Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder

THE GATEWAY: Live From DC After the FDA Psychedelics Hearing

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

PsychCentral – All About Psychedelic Therapy

PsychCentral – Microdosing Psychedelics Linked to Lower Anxiety, Depression, Stress

atai Life Sciences Reports Third Quarter 2022 Financial Results and Business...

Death, Dying, and Psychedelics

5-HT2A Virtual Chemical Screen Produces New Candidate Antidepressants

PT371 – The Trickster Archetype and the Need for Comic Relief

Reunion Neuroscience Schedules Fiscal Second Quarter 2023 Conference Call for Monday,...

Eyes on Oregon: Special Edition

MindMed to Host Earnings Call to Discuss Third Quarter 2022 Financial...

Opinions | The Facts on Colorado Proposition 122

EDITOR PICKS

No Questions Asked: FDA’s Psychedelics Public Hearing

Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder

THE GATEWAY: Live From DC After the FDA Psychedelics Hearing

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

No Questions Asked: FDA’s Psychedelics Public Hearing

Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder

THE GATEWAY: Live From DC After the FDA Psychedelics Hearing

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

PsychCentral – All About Psychedelic Therapy

PsychCentral – Microdosing Psychedelics Linked to Lower Anxiety, Depression, Stress

atai Life Sciences Reports Third Quarter 2022 Financial Results and Business...

Death, Dying, and Psychedelics

5-HT2A Virtual Chemical Screen Produces New Candidate Antidepressants

PT371 – The Trickster Archetype and the Need for Comic Relief

Reunion Neuroscience Schedules Fiscal Second Quarter 2023 Conference Call for Monday,...

Eyes on Oregon: Special Edition

MindMed to Host Earnings Call to Discuss Third Quarter 2022 Financial...

Opinions | The Facts on Colorado Proposition 122

EDITOR PICKS

No Questions Asked: FDA’s Psychedelics Public Hearing

Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder

THE GATEWAY: Live From DC After the FDA Psychedelics Hearing

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY